IBC’s Drug Discovery for Inflammatory Diseases offers an opportunity to receive a comprehensive update on the latest work in this field. You’ll learn about new targets in the signaling pathway upstream and downstream of the p38 MAP kinase, cytokine and chemokine receptor targets, academic and industry work in the new field of toll-like receptors and recent developments in the modulation of the GR and PPAR nuclear receptors. By attending, you’ll hear from thirty international experts in targeting the causes of chronic inflammation.